China Vanke (2202)
7.60 HKD -3.34 (-30.53%) Volume: 461.91M
China Vanke’s stock price stands at 7.60 HKD, witnessing a significant drop of 30.53% this trading session, despite a robust trading volume of 461.91M and an impressive YTD percentage growth of +17.31%, reflecting the dynamic nature of the real estate industry in China.
Latest developments on China Vanke
China Vanke (H) stock price experienced a significant drop today, with H-shares collapsing by 1,500 points or 6.8%. This sharp decline occurred amidst deals worth over $200 billion in just one hour of trading. The stock movements also had a ripple effect on brokers and other Chinese developers, causing them to tumble as well. Investors are closely monitoring the situation as the market reacts to these key events.
A look at China Vanke Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
China Vanke (H) is showing strong performance based on the Smartkarma Smart Scores. With a high score in Dividend and Momentum, the company is demonstrating stability and growth potential for investors. The Value score also indicates that the company is trading at an attractive price compared to its intrinsic value. However, the Growth and Resilience scores are slightly lower, suggesting some room for improvement in these areas.
Overall, China Vanke (H) appears to be a solid investment opportunity with its high Dividend and Momentum scores. Investors may find the company appealing for its stability and potential for growth. While there are areas for improvement in Growth and Resilience, the company’s strong performance in other areas bodes well for its long-term outlook in the property development sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
